WARSAW, Ind., Sept. 11, 2017 /PRNewswire/ — Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today announced the launch of the Persona® Partial Knee System, the latest addition to its portfolio of personalized and anatomically designed knee implant systems. The launch of the Persona Partial Knee System is the first significant jointly developed new product for the Company since the Zimmer Biomet combination, and reinforces the Company’s leadership position in partial knee replacement.
“The global introduction of the Persona Partial Knee System is the combined Company’s first major product launch and fills a significant gap in our knee portfolio,” said Daniel Florin, Interim Chief Executive Officer, Senior Vice President and Chief Financial Officer. “The partial knee market continues to expand as patients demand alternatives to traditional knee replacement. The addition of the fixed-bearing Persona Partial Knee System complements the Company’s mobile-bearing Oxford® Partial Knee, further strengthening our leadership position in this growing market.”
The Persona Partial Knee System represents the next era in personalization, equipping surgeons with a comprehensive system of implants and instruments that are designed to offer an uncompromising fit and efficiency in the operating room. The development team leveraged global experts in partial knee replacement and utilized the ZiBRA™ Anatomical Modeling System to analyze thousands of bones, both male and female, representing a diverse global population.
“The new Persona Partial Knee System has made me a better partial knee surgeon,” said Craig Della Valle, MD, a developing surgeon from Rush University Medical Center in Chicago, Illinois. “Its combination of compartment-specific implants that fit better to ergonomic instruments has made me both more accurate and efficient. The system is definitely a move forward in the right direction,” said Dr. Della Valle.
Rocci Trumper, MD, at Poudre Valley Hospital in Fort Collins, Colorado successfully performed the first surgery of the Persona Partial Knee System since the full global commercial launch on August 31, 2017. “The instruments were thoughtfully designed and the tibial component fit well,” said Dr. Trumper.
There have been more than 1,000 cases to date across centers in the U.S., EMEA and Japan, and more than 260 patients have been enrolled in a 10-year global multi-center study.
“The introduction of the Persona Partial Knee System comes at a significant time as we continue to see an increase in the demand for knee replacements,” said Dan Williamson, Zimmer Biomet’s Group President, Joint Reconstruction. “This innovative technology furthers our commitment to restore mobility, alleviate pain and improve the quality of life for patients around the world.”
About Zimmer Biomet
Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer Biomet is a global leader in musculoskeletal healthcare. We design, manufacture and market orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; office based technologies; spine, craniomaxillofacial and thoracic products; dental implants; and related surgical products.
We collaborate with healthcare professionals around the globe to advance the pace of innovation. Our products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Together with healthcare professionals, we help millions of people live better lives.
We have operations in more than 25 countries around the world and sell products in more than 100 countries. For more information, visit www.zimmerbiomet.com, or follow Zimmer Biomet on Twitter at www.twitter.com/zimmerbiomet.
Cautionary Statement Regarding Forward-Looking Statements
This release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning Zimmer Biomet’s expectations, plans, prospects, and product and service offerings, including new product launches and potential clinical successes. Such statements are based upon the current beliefs and expectations of management and are subject to significant risks, uncertainties and changes in circumstances that could cause actual outcomes and results to differ materially. For a list and description of some of such risks and uncertainties, see Zimmer Biomet’s periodic reports filed with the U.S. Securities and Exchange Commission (SEC). These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in Zimmer Biomet’s filings with the SEC. Forward-looking statements speak only as of the date they are made, and Zimmer Biomet disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers of this release are cautioned not to rely on these forward-looking statements, since there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary statement is applicable to all forward-looking statements contained in this release.
ZBH-Corp
SOURCE Zimmer Biomet Holdings, Inc.
Image courtesy of Zimmer Biomet.
